August 6, 2021 -- Qiagen announced it has received an emergency use authorization (EUA) from the U.S. Food and Drug Administration for its QIAreach SARS-CoV-2 Antigen Test, a rapid portable test that the company said can analyze over 30 samples per hour for the SARS-CoV-2 antigen.
The company touted its test, developed in collaboration with Ellume, as providing digital results in two to 15 minutes. It also uses Qiagen's Underwriters Laboratories (UL)-certified eHub, a portable reader with backup battery power that can be operated remotely from the main power for up to eight hours.
When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.Yes, Keep Me Current